Decrease in the effectiveness of bacille calmette-guérin vaccine against pulmonary tuberculosis: A consequence of increased immune suppression by microbial antioxidants, not overattenuation

Clinical Infectious Diseases

Volumn 51, Issue 2, 2010, Pages 177-184

  Kernodle, Douglas S ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GLUTAREDOXIN; PROTEIN DISULFIDE REDUCTASE (GLUTATHIONE); SUPEROXIDE DISMUTASE; THIOREDOXIN; THIOREDOXIN REDUCTASE; ANTIOXIDANT; IMMUNOSUPPRESSIVE AGENT; LIVE VACCINE;

ALTERNATIVE HYPOTHESIS; ANTIGEN PRESENTATION; ATTENUATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BCG VACCINATION; CLINICAL TRIAL; DRUG EFFICACY; EXPERIMENTAL MODEL; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENETIC IDENTIFICATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; CLINICAL TRIAL (TOPIC); GENETICS; IMMUNOLOGY; METABOLISM; MYCOBACTERIUM BOVIS; TUBERCULOSIS, PULMONARY;

ANTIOXIDANTS; BCG VACCINE; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOBACTERIUM BOVIS; TUBERCULOSIS, PULMONARY; VACCINES, ATTENUATED;

EID: 77954719364     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653533     Document Type: Review

References (55)

1. Bjartveit K. Olaf Scheel and Johannes Heimbeck: their contribution to understanding the pathogenesis and prevention of tuberculosis. Int J Tuberc Lung Dis 2003; 7:306-311.
2. Aronson JD, Aronson CF, Taylor HC. A twenty-year appraisal of BCG vaccination in the control of tuberculosis. Arch Intern Med 1958; 101:881-893.
3. Aronson NE, Santosham M, Comstock GW, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60- year follow-up study. JAMA 2004; 291:2086-2091.
4. Fine PEM, Carneiro IAM, Milstien JB, Clements JD. Issues relating to the use of BCG in immunization programs: a discussion document. Geneva, Switzerland: World Health Organization Department of Vaccines and Biologicals, 1999. Document WHO/V&B/99.23.
5. Ten Dam HG. BCG vaccination. In: Tuberculosis: a comprehensive international approach. Reichman LB, Hershfield ES, eds. New York: Marcel Dekker, 1993:251-274.
6. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a metaanalysis and assessment of cost-effectiveness. Lancet 2006; 367:1173-1180.
7. World Health Organization. Global tuberculosis control: surveillance, planning, financing. Geneva, Switzerland: World Health Organization, 2009.DocumentWHO/HTM/TB/ 2009.411.
8. Andersen P, Doherty TM. The success and failure of BCG: implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005; 3:656-662.
9. Edwards KM, Cynamon MH, Voladri RK, et al. Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2001; 164: 2213-2219.
10. Kurtz S, McKinnon KP, Runge MS, Ting JP, Braunstein M. The SecA2 secretion factor of Mycobacterium tuberculosis promotes growth in macrophages and inhibits the host immune response. Infect Immun 2006; 74:6855-6864.
11. Hinchey J, Lee S, Jeon BY, et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest 2007; 117:2279-2288.
12. Sadagopal S, Braunstein M, Hager CC, et al. Reducing the activity and secretion of microbial antioxidants enhances the immunogenicity of BCG. PLoS One 2009; 4:e5531.
13. Brosch R, Gordon SV, Buchrieser C, Pym AS, Garnier T, Cole ST. Comparative genomics uncovers large tandem chromosomal duplications in Mycobacterium bovis BCG Pasteur. Yeast 2000; 17:111-123.
14. Brosch R, Gordon SV, Garnier T, et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A 2007; 104: 5596-5601.
15. Irvine KN. B.C.G. vaccination in theory and practice. London, England: Blackwell Scientific Publications, 1949.
16. Dubos RJ, Pierce CH. Differential characteristics in vitro and in vivo of several substrains of BCG. I: Multiplication and survival in vitro. Am Rev Tuberc 1956; 74:655-666.
17. Dubos RJ, Pierce CH. Differential characteristics in vitro and in vivo of several substrains of BCG. II: Morphologic characteristics in vitro and in vivo. Am Rev Tuberc 1956; 74: 667-682.
18. Dubos RJ, Pierce CH, Schaefer WB. Differential characteristics in vitro and in vivo of several substrains of BCG. III: Multiplication and survival in vivo. Am Rev Tuberc 1956; 74:683-698.
19. Dubos RJ, Pierce CH. Differential characteristics in vitro and in vivo of several substrains of BCG. IV: Immunizing effectiveness. Am Rev Tuberc 1956; 74:699-717.
20. Yamamoto S, Yamamoto T. Historical review of BCG vaccine in Japan. Jpn J Infect Dis 2007; 60:331-336.
21. Bunch-Christensen K, Ladefoged A, Guld J. The virulence of some strains of BCG for golden hamsters: further studies. Bull World Health Organ 1970; 43:65-70.
22. Ladefoged A, Bunch-Christensen K, Guld J. Tuberculin sensitivity in guinea-pigs after vaccination with varying doses of BCG of 12 different strains. Bull World Health Organ 1976; 53:435-443.
23. Tuberculosis Prevention Trial. Trial of BCG vaccines in South India for tuberculosis prevention: first report. BullWorld Health Organ 1979; 57:819-827.
24. Wiegeshaus EH, Harding G, McMurray D, Grover AA, Smith DW. A co-operative evaluation of test systems used to assay tuberculosis vaccines. Bull World Health Organ 1971; 45:543-550.
25. Comstock GW. Identification of an effective vaccine against tuberculosis. Am Rev Respir Dis 1988; 138:479-480.
26. Comstock GW. Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies. Epidemiol Rev 1994; 16: 77-89.
27. ComstockGW. Simple, practical ways to assess the protective efficacy of a new tuberculosis vaccine. Clin Infect Dis 2000; 30(suppl 3): S250-S253.
28. Sher NA, Chaparas SD, Pearson J, Chirigos M. Virulence of six strains of Mycobacterium bovis (BCG) in mice. Infect Immun 1973; 8: 736-742.
29. Lagranderie MR, Balazuc AM, Deriaud E, Leclerc CD, Gheorghiu M. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun 1996; 64:1-9.
30. Milstein JB, Gibson JJ. Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ 1990; 68:93-108.
31. Mahomed H, Kibel M, Hawkridge T, et al. The impact of a change in bacille Calmette- Guerin vaccine policy on tuberculosis incidence in children in Cape Town, South Africa. Pediatr Infect Dis J 2006; 25:1167-1172.
32. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996; 178: 1274-1282.
33. Lewis KN, Liao R, Guinn KM, et al. Deletion of RD1 from Mycobacterium tuberculosismimics bacille Calmette-Guerin attenuation. J Infect Dis 2003; 187:117-123.
34. Hsu T, Hingley-Wilson SM, Chen B, et al. The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc Natl Acad Sci U S A 2003; 100:12420-12425.
35. Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by wholegenome DNA microarray. Science 1999; 284: 1520-1523.
36. Behr MA, Small PM. Has BCG attenuated to impotence? Nature 1997; 389:133-134.
37. Mostowy S, Tsolaki AG, Small PM, Behr MA. The in vitro evolution of BCG vaccines. Vaccine 2003; 21:4270-4274.
38. H. J Bacteriol 2009; 191:3965-3980.
39. σH in Mycobacterium tuberculosis global gene expression. Mol Microbiol 2002; 45:365-374.
40. Aronson JD, Schneider P. The problem of standardization of BCG vaccine. Am J Public Health 1950; 40:533-544.
41. Kaushal D, Schroeder BG, Tyagi S, et al. Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative σ factor, SigH. Proc Natl Acad Sci U S A 2002; 99:8330-8335.
42. Alexander DC, Behr MA. Rv1773 is a transcriptional repressor deleted from BCG-Pasteur. Tuberculosis (Edinb) 2007; 87:421-425.
43. Woodworth JS, Behar SM. Mycobacterium tuberculosis- specific CD8+ T cells and their role in immunity. Crit Rev Immunol 2006; 26:317-352.
44. Carranza C, Juarez E, Torres M, Ellner JJ, Sada E, Schwander SK. Mycobacterium tuberculosis growth control by lung macrophages andCD8 cells from patient contacts. Am J Respir Crit Care Med 2006; 173:238-245.
45. Davids V, Hanekom WA, Mansoor N, et al. The effect of bacille Calmette-Guerin vaccine strain and route of administration on induced immune responses in vaccinated infants. J Infect Dis 2006; 193:531-536.
46. Olsen AW, Brandt L, Agger EM, van Pinxteren LAH, Andersen P. The influence of remaining live BCG organisms on the maintenance of immunity to tuberculosis. Scand J Immunol 2004; 60:273-277.
47. Sinha A, Singh A, Satchidanandam V, Natarajan K. Impaired generation of reactive oxygen species during differentiation of dendritic cells (DCs) by Mycobacterium tuberculosis secretory antigen (MTSA) and subsequent activation of MTSA-DCs by mycobacteria results in increased intracellular survival. J Immunol 2006; 177:468-478.
48. Lee PP, Chan KW, Jiang L, et al. Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. Pediatr Infect Dis J 2008; 27: 224-230.
49. Bustamante J, Aksu G, Vogt G, et al. BCGosis and tuberculosis in a child with chronic granulomatous disease. J Allergy Clin Immunol 2007; 120:32-38.
50. Donaldson M, Antignani A, Milner J, et al. p47phox-deficient immune microenvironment signals dysregulate naive T-cell apoptosis. Cell Death Differ 2009; 16:125-138.
51. Siddiqi M, Garcia ZC, Stein DS, Denny TN, Spolarics Z. Relationship between oxidative burst activity and CD11b expression in neutrophils and monocytes from healthy individuals: effects of race and gender. Cytometry 2001; 46:243-246.
52. Martineau AR, Newton SM, Wilkinson KA, et al. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest 2007; 117:1988-1994.
53. Arroyo M, Modriansky M, Serinkan FB, et al. NADPH oxidase-dependent oxidation and externalization of phosphatidylserine during apoptosis in Me2SO-differentiated HL-60 cells: role in phagocytic clearance. J Biol Chem 2002; 277:49965-49975.
54. Gil DP, Leon LG, Correa LI, et al. Differential induction of apoptosis and necrosis in monocytes from patients with tuberculosis and healthy control subjects. J Infect Dis 2004; 189: 2120-2128.
55. Hesseling AC, Johnson LF, Cotton MF, et al. Disseminated bacille Calmette-Guerin disease in HIV-infected South African infants. Bull World Health Organ 2009; 87:505-511.